about
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA NephropathyIdarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available EvidenceAnticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity.Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.Nephrology
P2860
Q35187005-002B8125-CC8F-4708-A542-0117B0646F85Q35683869-A3D59EC4-9582-45EA-A42A-7B5C57F8FFF4Q35968902-D375B8AB-3D72-4A64-922A-8E95B27B58C1Q38624595-C9A94466-194A-4381-B11B-9BDE8EBB6B86Q39120056-512C861A-CA09-49A0-B40D-76A2AED7D7A3Q48375140-882B5BC1-036B-4A41-9DDA-F447105CA55AQ59192050-AF2D19C0-E992-419B-9100-312FA155ECDB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dabigatran and kidney disease: a bad combination.
@en
type
label
Dabigatran and kidney disease: a bad combination.
@en
prefLabel
Dabigatran and kidney disease: a bad combination.
@en
P2093
P2860
P356
P1476
Dabigatran and kidney disease: a bad combination.
@en
P2093
C Michael Chaknos
Felix Knauf
Jeffrey S Berns
Mark A Perazella
P2860
P304
P356
10.2215/CJN.01260213
P577
2013-07-18T00:00:00Z